In paclitaxel-resistant ovarian cancer cells, blocking of STAT3 activity suppresses STAT3 downstream antiapoptotic regulatory genes BCL2L1, MCL1, and BIRC5, which increases paclitaxel sensitivity in paclitaxel-resistant ovarian cancer cells in vitro [56]. Here, BIRC5 is linked to ovarian carcinoma.